Sai Parenteral’s Ltd. is approaching its IPO with a clear strategic intent—transitioning from a capacity-led growth phase to a more integrated, innovation-driven pharmaceutical platform. The company focuses on scaling manufacturing capabilities, strengthening regulatory compliance, and deepening its presence in global markets.
Key highlights
- ₹111 crore capex towards capacity expansion and EU-GMP upgrades
- ₹18 crore investment in R&D to strengthen development capabilities
- Focus on regulated markets through compliance-led manufacturing
- Under-construction Australia facility to enhance global presence
- IPO size of ₹408.79 crore including ₹285 crore fresh issue and ₹123.79 crore in OFS
Capital allocation often reveals more about a company’s future than its past. For Sai Parenteral’s Limited, the planned growth capex out of IPO proceeds is not just an investment cycle—it is the culmination of a multi-year strategy to build an integrated, globally relevant pharmaceutical platform.
Over the past few years, the Company has focused on strengthening its foundations—expanding manufacturing capabilities, building a portfolio of product dossiers, and entering regulated markets through strategic acquisitions. The current capex plan reflects the next phase of this journey: scaling these capabilities into a more structured and globally integrated platform.
he Company plans to deploy ₹111 crore towards capacity expansion and upgradation of its manufacturing facilities in India, with a primary focus on aligning its plants with EU-GMP standards. This is expected to enable deeper participation in regulated and semi-regulated markets, where compliance and quality serve as key entry barriers.
These investments are closely linked to the Company’s broader strategy. Enhanced manufacturing capabilities, when combined with its growing IP portfolio and regulatory access, are expected to support faster product commercialisation and strengthen its CDMO and export branded generics business.
Anil KK, Chairman & Managing Director, SAI Parenteral’s Limited, said:
“Investments in manufacturing and R&D are key to our next phase of growth as we expand into regulated markets.”
In parallel, the planned investment of ₹18 crore in a dedicated R&D centre reflects a continued focus on moving up the value chain—from manufacturing to development and product ownership. This facility is expected to support formulation development, regulatory filings, and product scale-up for international markets.
Additionally, the under-construction manufacturing facility in Adelaide, Australia, with a total capex of ₹311 crores through Noumed, is expected to enhance supply chain resilience and strengthen the Company’s presence in regulated markets.
Taken together, the capex plan reflects a clear strategic intent—building on past investments while positioning the Company for its next phase of growth in the global pharmaceutical landscape.
Sai Parenteral IPO
SAI Parenteral’s ₹409 crore IPO is open from March 24 to March 27. The issue size is ₹408.79 crore including ₹285 crore fresh issue and ₹123.79 crore in OFS from non-promoter shareholders.
The company is backed by marquee investors including Samarsh Capital (backed by Mr. Mohandas Pai), Dr. B. Bhaskara Rao (MD, KIMS Hospitals), Blue Lotus Capital, Polycab promoters, and Gruhas Proptech (backed by Mr. Nikhil Kamath and Mr. Abhijeet Pai).
Issue opens Mar 24, 2026 | Closes Mar 27, 2026 | Listing expected Apr 2, 2026
Click here to check more details on Sai Parenteral IPO
